Research

Hormonal

Women with non-diabetic obesity experience greater cardiovascular benefits from GLP-1 RAs, particularly regarding heart failure hospitalization and stroke reduction, compared to men.

Women with obesity may derive even greater heart protection from GLP-1 medications than men, especially regarding heart failure prevention. This is particularly true for postmenopausal women who are at higher risk for heart failure with preserved ejection fraction (HFpEF). Discussing your specific heart failure risk with your provider is crucial.

LimitedQualifiesMEDIUM confidence
Women (n=9,847, 63.8% of participants) demonstrated MACE reduction of 22% (RR 0.78, 95% CI 0.67-0.91, P=0.001)... However, women showed stronger heart failure hospitalization reduction (RR 0.73, 95% CI 0.58-0.92, P=0.008) compared to men (RR 0.94, 95% CI 0.75-1.18, P=0.59, P interaction=0.09)
Kehinde Tom-Ayegunle et al. · Cureus · 2026

Why this rating

Subgroup analysis of a high-quality meta-analysis; moderate quality evidence for HF hospitalization due to heterogeneity.

Source

Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis

Kehinde Tom-Ayegunle et al. · Cureus · 2026

DOI 10.7759/cureus.100947

Meta-analysis · 16 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →